Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The company’s lead product candidate is crisaborole topical ointment, 2%, anti-inflammatory phosphodiesterase-4 inhibitor, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis. It is also developing AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria. The company has collaboration agreements with the Global Alliance for Livestock Veterinary Medicines to develop drug candidates for the treatment and prevention of African trypanosomiasis in cattle; Drugs for Neglected Diseases initiative to develop new therapeutics for human African trypanosomiasis (TB), visceral leishmaniasis, and Chagas disease; GlaxoSmithKline LLC for tuberculosis; Eli Lilly and Company for an animal health indication; and The Bill & Melinda Gates Foundation for filarial worm diseases, TB, and cryptosporidiosis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California. As of June 23, 2016, Anacor Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.